N/A
Completed N=38
A Study On The Efficacy Of Macugen Injections In Patients With Neovascular Age-Related Macular Degeneration In Real Life.
Source: ClinicalTrials.gov NCT00549055 ↗Enrolled (actual)
38
Serious AEs
0.0%
Results posted
Oct 2010
Primary outcomePrimary: Change From Baseline to Final Visit in Visual Acuity (VA) Score — -0.044 Scores on scale
Summary
To assess effectiveness of Macugen for treatment of neovascular age-related macular degeneration by measuring the evolution of visual acuity. Treatment duration, frequency of administration and combination with other treatments will also be evaluated.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Change From Baseline to Final Visit in Visual Acuity (VA) Score |
-0.044 | — |
| SECONDARY Number of Participants With Change in VA: Improvement |
3; 1; 1; 1 | — |
| SECONDARY Number of Participants With Change in VA: Stabilization |
11; 2; 0; 1 | — |
| SECONDARY Number of Participants With Change in VA: Worsening |
4; 2; 1; 0 | — |
| SECONDARY Duration of Treatment |
4.66 | — |
| SECONDARY Frequency of Macugen Administration |
7.74 | — |
| SECONDARY Number of Participants Who Received Other Concomitant Age Related Macular Degeneration (AMD) Treatments |
4 | — |
Eligibility Criteria
Inclusion Criteria
- Patients diagnosed with subfoveal neovascular (wet) age-related macular degeneration
- Patients having received at least 1 Macugen injection
- Treatment naive patients, or patients having received conventional therapy
- Patients having signed and dated informed consent.
Exclusion Criteria
- Patients participating in another clinical study with Macugen.
Data sourced from ClinicalTrials.gov (NCT00549055). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.